[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"burn-wounds---partial-thickness-2nd-degree\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:burn-wounds---partial-thickness-2nd-degree":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100618899","field-shield-wound-dressing-study-100618899",false,"NCT07337616","Field Shield Wound Dressing Study","Clinical Assessment of Field Shield Wound Dressing of Large Surface Area Burn Wounds","Inclusion Criteria:\n\n* Thermal injury size 5-30% TBSA\n* Admitted to the burn center and enroll able within 72 hours of injury\n* Subject has two distinct areas of 100cm2 or larger of intermediate to deep partial thickness burns (study sites). These areas are judged to be comparable in depth.\n* The subject and or caregiver is able and willing to follow the protocol requirements\n* Achieve wound photos and dressing change at 3 days\n\nExclusion Criteria:\n\n* Subject has congestive heart failure, oxygen-dependent chronic lung disease, end-stage renal disease, or liver cirrhosis\n\n  * Subject is undergoing hospice care.\n  * Subject is currently being treated for an active malignant disease\n  * Subject has other concurrent conditions that in the opinion of the Investigator may compromise subject safety\n  * Known contraindications to silver metals, silver chloride, or silver tetraoxide\n  * Known contraindications to lidocaine\n  * Known allergies to any components of either primary dressing in the study\n  * Known allergies to the silicone or adhesives in secondary dressings\n  * Burns located on the hands, feet, face, and\u002For genitals will be excluded from treatment sites, but will be included in the total TBSA calculation\n  * Subject has a combined TBSA of 31% or greater of partial and\u002For full thickness burn wounds\n  * Concurrent participation in another clinical trial that involves an investigational drug or device that would interfere with this study.\n  * Subject is pregnant, breast feeding, or planning to become pregnant.\n  * Subjects who, within 60 days prior to enrollment, have a history of more than two weeks treatment with immunosuppressants (including systemic corticosteroids \\>10mg daily dose), cytotoxic chemotherapy, application of topical steroids within one month prior to enrollment, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study.\n  * Burn study site(s) has been previously treated with tissue engineered materials (e.g., Apligraf® or Dermagraft®) or other scaffold materials (e.g., Oasis, Matristem) preceding the study wound dressing application.\n  * Burn study site(s) has been previously treated with a silvadene","ALL","18 Years","75 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study is to compare the Field Shield Wound Dressing (FSWD) as a treatment for burn wounds to a standard of care burn wound dressing to evaluate healing, infection, pain\u002Fdiscomfort, and deepening of wound over time.",[27],"Burn Wounds - Partial Thickness (2nd Degree)",[29,30],"FSWD","Burn wounds","RECRUITING","2026-01-12",{"date":34,"type":35},"2026-01-13","ACTUAL",{"date":37,"type":35},"2025-05-01",{"date":39,"type":21},"2026-09-29",{"name":41,"class":42},"KeriCure Medical","INDUSTRY",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100594896","phase-2-phase-ii-clinical-trial-of-kj101in-the-treatment-of-deep-ii-degree-burns-100594896","NCT07025408","Phase II Clinical Trial of KJ101in the Treatment of Deep II Degree Burns","A Multicentre, Randomised, Double-blind, Dose-exploratory, Controlled Drug and Placebo-controlled Phase II Clinical Trial Evaluating the Safety, Efficacy, Pharmacokinetic Profile, and Immunogenicity of KJ101 for Wound Debridement in Deep II Degree Burns","Inclusion criteria:\n\n1. Male and female subjects aged 18 to 65 years inclusive, who are neither pregnant nor lactating;\n2. Clinically diagnosed with superficial or deep II degree burns within 72 hours of injury, with a total burn area of ≤30% TBSA. The target burn wound must be isolated or have distinguishable boundaries, with an area between 40 and 200 cm².\n3. Subjects of childbearing age must agree to use effective and safe contraceptive methods during the treatment period and for three months after the final administration.\n\nExclusion criteria:\n\n1. Individuals who are known to be allergic to any component of the test drug or who have a tendency to allergies.\n2. Burns caused by specific factors, such as electrical or chemical burns.\n3. Subjects with shock or inhalation lung injury;\n4. Subjects with target wounds complicated by inflammatory skin diseases (e.g. atopic dermatitis, eczema or psoriasis), or who have undergone enzymatic debridement (e.g. with collagenase, papain, bromelain, chymotrypsin or trypsin).\n5. Subjects who, during screening, are judged by the investigator to have other severe systemic infections requiring systemic treatment;\n6. Abnormal liver or kidney function.","65 Years",{"count":52,"type":21},144,[54],"PHASE2","This multicentre, randomised, double-blind, dose-finding, active- and placebo-controlled Phase II clinical trial will evaluate the safety, efficacy, pharmacokinetic profile, and immunogenicity of KJ101 for the debridement of deep second-degree burns. The trial will provide supporting evidence for subsequent Phase III trials.",[57,27],"Burn","2025-06-10",{"date":60,"type":35},"2025-06-17",{"date":62,"type":21},"2025-06-16",{"date":64,"type":21},"2026-08-29",{"name":66,"class":42},"Shanghai Bao Pharmaceuticals Co., Ltd.",1]